Tmunity Therapeutics logo

Tmunity Therapeutics Funding & Investors

Philadelphia, PA

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunityโ€™s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.

tmunity.com

Total Amount Raised: $220,000,000

Tmunity Therapeutics' Investors

Tmunity Therapeutics Funding Rounds

  • Series B

    $75,000,000

    Series B Investors

    Andreessen Horowitz
    Gilead Sciences
    Be The Match BioTherapies
    Westlake Village BioPartners
    BrightEdge Fund
    Penn Medicine Co-Investment Program
  • Series A

    $35,000,000

    Series A Investors

    Gilead Sciences
    Ping An Ventures
    Parker Institute for Cancer Immunotherapy
    Be The Match BioTherapies
    Lilly Asia Ventures
    Kleiner Perkins
    Penn Medicine Co-Investment Program
    University of Pennsylvania (Penn)
  • Series A

    $100,000,000

    Series A Investors

    Ping An Ventures
    Parker Institute for Cancer Immunotherapy
    Gilead Sciences
    Be The Match BioTherapies
    Lilly Asia Ventures
    University of Pennsylvania (Penn)
  • Seed

    $10,000,000

    Seed Investors

    Lilly Asia Ventures
    Parker Institute for Cancer Immunotherapy
    Penn Medicine Co-Investment Program
Funding info provided by Diffbot.